DailyIQ
|
DailyIQ
|
Sector:HealthcareAll sectors
Last updatedUpdating…

ARGX·Argenx SE American Depositary Shares

$918.69
+23.92 (+2.67%)
High
$922.62
Open
$894.87
Market Cap
51.25B
52W High
$1,074.70
Low
$886.18
P. Close
$918.69
P/E
21.82
52W Low
$661.56
Fwd P/E
26.86
DailyIQ Est.
$1202.63
Inst. Own.
33.9%
Short Interest
2.43%
Days to Cover
2.5
Technical Score (1D)
57
BULLISH
News Sentiment
55
BULLISH
On Nov 3, 2026, argenx announced that members of its management team would attend two investor conferences in November. The company scheduled a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference on Nov 10 in Boston and another at the Jefferies London Global Healthcare Conference on Nov 17 in London. Live webcasts of the presentations would be available on argenx’s investor website, with replays accessible for approximately 30 days. The announcement highlighted argenx’s ongoing engagement with investors and its commitment to transparency. No additional developments were reported on that date.
LOW TARGET
$861 -6.3%
1 analysts
MEAN TARGET
$1147 +24.9%
14 analysts
HIGH TARGET
$1353 +47.3%
13 analysts
PRICE RANGE
$861.00 - $1353.00
SB / B / H / S / SS
8/15/3/1/1
DAILYIQ EST.
$1202.63 (+30.9%)
Sector
Healthcare
Industry
Biotechnology
Exchange
NMS
Country
Netherlands
Website
argenx.com
Symbol
ARGX
Description
argenx SE is a commercial-stage biotechnology company focused on developing innovative therapies for autoimmune diseases. Its core product, VYGART, is approved for treating generalized myasthenia gravis (gMG) and other conditions, with a subcutaneous formulation, VYGART HYTRULO, also available. argenx has a robust pipeline of investigational treatments, including efgartigimod, targeting a range of autoimmune disorders such as ocular gMG and immune thrombocytopenia (ITP). The company's research also explores therapies for conditions like multifocal motor neuropathy and congenital myasthenic syndrome. argenx SE leverages strategic collaborations with various pharmaceutical and research organizations to advance its drug development programs and expand its global presence.
92/ 100
Strong bullish
Overall: Bullish
✓Analyst target above current price
View full financials →
Earnings Summary
In Q4 2024, the company reported EPS of $0.71 against an estimate of $1.70, missing expectations, while revenue of $724 million was in line with prior guidance; in Q2 2026, EPS of $7.32 beat an estimate of $6.19, and revenue of $1.542 billion slightly underperformed the $1.567 billion estimate, indicating strong earnings but modest revenue pressure; Q3 2026 saw EPS of $7.80 versus an estimate of -$27.83, a dramatic beat, with revenue of $1.751 billion versus an estimate of $1.892 billion, reflecting a slight revenue shortfall. Historically, argenx has shown a YoY revenue growth of approximately 15% in 2025 and 2026, with EPS growth accelerating from $0.71 in Q4 2024 to $7.32 in Q2 2026, yet revenue has occasionally lagged estimates, suggesting pricing or sales volume challenges. Recent news highlights positive Phase 3 trial results for VYVGART in immune‑mediated necrotizing myopathy and dermatomyositis, a potential catalyst for future sales, alongside market commentary that the stock trades below analyst targets, raising valuation concerns; no specific earnings guidance was disclosed.

EPS

EstBeatMiss
$-33.17$-21.59$-10.01$1.56$13.14Q4'24Q2'26Q3'26
QtrEstActual+/−
Q3'26$-27.83$7.80+128.0%
Q2'26$6.19$7.32+18.2%
Q4'24$1.70$0.71-58.0%

Revenue

EstBeatMiss
$549M$929M$1.3B$1.7B$2.1BQ4'24Q2'26Q3'26
QtrEstActual+/−
Q3'26$1.9B$1.8B-7.5%
Q2'26$1.6B$1.5B-1.6%
Q4'24 - $724M -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

ARGX Stock Snapshot

NEUTRAL57/100
$918.69+$23.92 (2.7%)
Market cap
51.25B
P/E ratio
21.8
Day range
$886.18 – $922.62
News sentiment
55/100 · Neutral
Analyst target
$1147.35 (+24.9%)
Consensus
Buy · 28 analysts
52-week range+38.9% off low · -14.5% from high
$661.56$1074.70
Price $918.69 DailyIQ Est. $1202.63

Momentum has flattened on ARGX, leaving the next move dependent on news rather than the chart. Sector peers are worth watching - large caps in Healthcare tend to move together on rotation.

Sector Rotation

Is money rotating into or out of ARGX's sector?

Argenx SE American Depositary Shares sits in the Health Care sector, currently ranked 1st of 12 GICS sectors by relative-strength rotation score (weakening). Within its narrower Retail industry group, ARGX ranks 3rd of 15 tracked industries, leading.

Sector rank
#1 of 12
Sector state
Weakening
Sector rotation score
100
Industry rank
#3 of 15

Options Market

What is the options market pricing for ARGX?

CallsPuts

For Argenx SE American Depositary Shares's nearest expiry (2026-11-20, 14 days out), open interest is put-heavy, a defensive/bearish tilt (put/call ratio of 1.80), with at-the-money implied volatility around 44.0%. The options market is pricing roughly a ±8.9% move by that expiry — a range of about $838.93–$1001.97.

Put/call ratio (2026-11-20)
1.80
ATM implied volatility
44.0%
Total open interest
3,696
Expected move by 2026-11-20
±8.9% ($838.93–$1001.97)

Analyst Consensus Estimates

What do analysts expect ARGX to earn?

Analysts expect Argenx SE American Depositary Shares to earn $28.27 per share in the fiscal year ending Dec 2026 and $57.90 in the fiscal year ending Dec 2029, from 5 estimates. These are analyst forecasts, not company guidance, and later years rest on fewer analysts.

Quarter endingEPS estimateEPS rangeEPS analystsRevenue estimateRevenue analysts
Dec 2026$7.32$6.56 to $8.082$1.89B2
Mar 2027$6.49$6.49 to $6.491$1.85B1
Jun 2027$8.27$7.83 to $8.905~$1.82B-
Sep 2027$9.22$8.67 to $9.875~$2.03B-
Fiscal year endingEPS estimateEPS rangeEPS analystsRevenue estimateRevenue analysts
Dec 2026$28.27$27.16 to $29.454$6.37B5
Dec 2027$33.31$31.68 to $34.744$7.77B5
Dec 2028$47.03$38.86 to $56.288~$10.35B-
Dec 2029$57.90$45.43 to $77.905~$12.74B-

Revenue marked ~ is our calculation from the EPS estimate, not analyst consensus.

Analyst Rating Changes

Are analysts turning bullish or bearish on ARGX?

Citigroup most recently reiterated its rating on Argenx SE American Depositary Shares to Buy on Oct 27, 2026 with a price target of $1232 (from $1301). Over the last 90 days, coverage has run 1 upgrade against 0 downgrades, a net bullish lean.

Latest action
Citigroup: Buy
90-day upgrades
1
90-day downgrades
0
Net rating momentum
+1
DateFirmActionRatingPrice target
Oct 27, 2026CitigroupMaintainedBuy$1301 → $1232
Oct 23, 2026Morgan StanleyMaintainedOverweight$1140 → $1190
Oct 23, 2026GuggenheimMaintainedBuy$1185 → $1120
Oct 23, 2026Wells FargoMaintainedOverweight$1356 → $1336
Oct 23, 2026Evercore ISI GroupMaintainedOutperform$1078 → $1090
Oct 23, 2026BairdMaintainedNeutral$823 → $861
Oct 20, 2026RBC CapitalMaintainedOutperform$1100 → $1025
Oct 14, 2026Wells FargoMaintainedOverweight$1355 → $1356
Oct 12, 2026OppenheimerMaintainedOutperform$1100 → $1038
Oct 9, 2026Evercore ISI GroupMaintainedOutperform$1175 → $1078
Oct 9, 2026BairdMaintainedNeutral$932 → $823
Sep 8, 2026WedbushReiteratedOutperform$1150

Peers & ETF holders

ARGX peers & ETF holders

BiotechnologyMarket cap · today

Top ETF holdersWeight

News & sentiment

What is the news saying about ARGX?

ARGX fell 1.4% over the month to Nov 6. News tone held between 0 and 92 from Oct 6 to Oct 21, then dropped to 47 on Oct 22.

Daily close and news tone, Oct 6 to Nov 6
$800$900Oct 6: tone 70Oct 7: tone 0Oct 8: tone 33Oct 9: tone 44Oct 12: tone 30Oct 13Oct 14: tone 64Oct 15: tone 67Oct 16: tone 92Oct 19: tone 76Oct 20: tone 54Oct 21: tone 92Oct 22: tone 47Oct 23: tone 66Oct 26: tone 57Oct 27: tone 35Oct 28Oct 29: tone 57Oct 30: tone 70Nov 2Nov 3: tone 56Nov 4Nov 5Nov 6Oct 6News toneNov 6123
  1. Oct 8 -11.7%same day: argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease
  2. Oct 20 +5.1%same day: RBC Capital Maintains Outperform on argenx, Lowers Price Target to $1025
  3. Nov 5 -3.9%
Latest stories naming Argenx SE American Depositary Shares

Technical analysis

How strong is ARGX's momentum right now?

On the daily chart ARGX ranks at the 57th percentile for momentum against 1,060 stocks and ETFs, a neutral reading.

Momentum rank by timeframe0 = weakest, 100 = strongest
See what drives the rankThe inputs behind each timeframe's momentum rank, plus RSI, stochastics, Bollinger Bands and moving averages. Free with an account.

Institutional ownership

Are big funds buying or selling ARGX?

60 of the 134 tracked managers added to ARGX in their latest 13F and 72 trimmed. Together they own 33.9% of the company, worth $17.4B. Fidelity and Capital World Investors alone hold 13.3%.

60adding72trimming2unchanged
Largest holders by stake, latest 13FBar = share of ARGX
  1. 1FMR LLC (Fidelity)9.39%
    $4.9B positionAdded 4.8% last quarter
  2. 2Capital World Investors3.95%
    $2.0B positionTrimmed 2.5% last quarter
  3. 3Artisan Partners Limited Partnership2.71%
    $1.4B positionAdded 2.8% last quarter
  4. 4Wellington Management Group LLP1.67%
    $863.3M positionTrimmed 8.9% last quarter
  5. 5BlackRock, Inc.1.40%
    $721.1M positionTrimmed 3.8% last quarter
  6. 6Morgan Stanley1.15%
    $596.7M positionAdded 14.7% last quarter
  7. 7Invesco Ltd.0.80%
    $411.9M positionTrimmed 25.3% last quarter
  8. 8Bank of America Corp0.72%
    $371.3M positionAdded 0.0% last quarter
  9. 9AllianceBernstein L.P.0.71%
    $288.9M positionTrimmed 6.3% last quarter
  10. 10Sands Capital Management, LLC0.54%
    $277.0M positionTrimmed 12.3% last quarter
Full holdings history

Congressional trading

Is Congress trading ARGX?

1 member of Congress disclosed 1 ARGX trade on Mar 30, 2026: 1 buy, about $8.0K in estimated value.

BuysSellsMar
BuySell$1K–$15K$15K–$50K$50K–$100K$100K–$250K
Full trading history

Discover more

How has ARGX done against its peers?

Over the six months to Nov 6, ARGX returned +13.8%. Of the 15 related stocks and ETFs, 10 did better, led by EXEL at +43.3%.

Change since May 6, through Nov 6
−50%−25%0%+25%+50%May 6JunJulAugSepOctNov 6EXEL +43.3%ARGX +13.8%ZTS −28.9%